Empirico has filed a notice of an exempt offering of securities to raise $55,222,199.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Empirico is raising $55,222,199.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Omri Gottesman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Empirico
Empirico is a venture-backed, next-generation therapeutics company founded on utilizing huge biological data sets, human genetics and programmable biology to power novel target discovery and development. Empiricos Precision Insights Platform was purpose-built for therapeutic discovery and leverages a world-leading dataset and advanced algorithmic approaches to identify and prioritize therapeutic targets with a high probability of translational success. High priority therapeutic targets are experimentally validated in-house prior to progressing through pre-clinical development with the most optimal therapeutic modality. Empirico is headquartered in San Diego, CA with laboratories in Madison, WI.
To learn more about Empirico, visit http://www.empiricotx.com/
Contact:
Omri Gottesman, Chief Executive Officer
347-725-0022
https://www.linkedin.com/in/omri-gottesman-99835458/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.